827-33-8

Usage

Uses

Used in Pharmaceutical Industry:
4-bromo-5-chloro-2-nitrophenylamine is used as a building block for the synthesis of various drugs and pharmacologically active compounds due to its unique chemical structure and reactivity.
Used in Dye Production:
4-bromo-5-chloro-2-nitrophenylamine is used as an intermediate in the production of dyes, contributing to the development of new colorants with specific properties.
Used in Agricultural Chemicals:
4-bromo-5-chloro-2-nitrophenylamine is utilized as an intermediate in the production of agricultural chemicals, potentially enhancing the effectiveness of these products.
Safety Precautions:
It is crucial to handle and store 4-bromo-5-chloro-2-nitrophenylamine with proper safety measures, as it may be harmful if ingested, inhaled, or comes into contact with the skin.

Upstream product

• 22459-81-0 N-(4-bromo-3-chlorophenyl)acetamide 
• 588-07-8 3-Chloroacetanilide 
• 1635-61-6 5-chloro-2-nitroaniline 
• 21402-26-6 4-bromo-3-chloroaniline 
• 956282-97-6 N-(4-bromo-5-chloro-2-nitro-phenyl)-2,2,2-trifluoro-acetamide 
• 716-66-5 N-(4-bromo-5-chloro-2-nitrophenyl)acetamide 

Downstream Products

• 716-66-5 N-(4-bromo-5-chloro-2-nitrophenyl)acetamide 
• 1388057-23-5 5-bromo-6-chloro-1H-benzo[d]imidazol-2(3H)-one 
• 1346665-78-8 4-(6-chlorobenzo[c][1,2,5]oxadiazol-5-yl)aniline 
• 1346665-81-3 C₁₉H₁₀ClF₂N₃O₂ 
• 75293-98-0 N-ethoxycarbonylacetyl 2-nitro-4-bromo-5-chloro-aniline 

Relevant academic research and scientific papers

PYRAZOLES AS MODULATORS OF HEMOGLOBIN

The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula

HETEROARYL RHEB INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. Compositions comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of the compound in compositions of this invention is such that it is effective to measurably inhibit Rheb, in a biological sample or in a patient.

HETERO-CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME

The present specification relates to a heterocyclic compound represented by chemical formula 1 and an organic light emitting device comprising the same. The heterocyclic compound may be used as a material of an organic material layer of an organic light e

HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES

Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFRβ kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

SERINE/THREONINE PAK1 INHIBITORS

Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF

The present application relates to novel substituted 5-aminopyrazoles, methods of production thereof, use thereof alone or in combinations for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases.

Benzimidazole Modulators of VR1

The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.

Crystal packing: An examination of the packing of molecules approximately isosteric with 4,5-dichlorophthalic anhydride

The crystal structures of five 5,6-disubstituted benzofurazan 1-oxides are presented and compared with five previously reported structures: three polymorphs of 5,6-dichlorobenzofurazan 1-oxide plus 4,5-dichloro- and 4,5-dibromophthalic anhydride. All but one of these compounds pack with similar two-dimensional layers. The benzofurazan oxides all show disorder about a crystallographic twofold or pseudo-twofold axis. In addition, six complexes of phthalic anhydride and benzofurazan oxides are reported. With the packing in the complexes principally directed by the π complexing, the disorder, invariably found in the uncomplexed benzofurazan oxides, is diminished, and, in two cases, eliminated.